Alaunos Therapeutics (FRA:WEK) Other Income (Expense) : €-4.35 Mil (TTM As of Dec. 2023)

View and export this data going back to 2006. Start your Free Trial

What is Alaunos Therapeutics Other Income (Expense)?

Alaunos Therapeutics's other income expense for the Alaunos Therapeutics's pretax income for the three months ended in Dec. 2023 was €-4.11 Mil. Its other income expense for the trailing twelve months (TTM) ended in Dec. 2023 was €-4.35 Mil.

Alaunos Therapeutics Other Income (Expense) Historical Data

The historical data trend for Alaunos Therapeutics's Other Income (Expense) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alaunos Therapeutics Other Income (Expense) Chart

Alaunos Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Income (Expense)

Get a 7-Day Free Trial

-53.94

0.32

-0.67

0.63

-4.33

Alaunos Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Other Income (Expense)	Get a 7-Day Free Trial															0.24	0.45	0.48	-1.16	-4.11

Alaunos Therapeutics Other Income (Expense) Calculation

Other income expense includes minority interest. Minority interest is a significant but non-controlling ownership of less than 50% of a company's voting shares by either an investor or another company.

Other Income (Expense) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-4.35 Mil.

Alaunos Therapeutics (FRA:WEK) Other Income (Expense) Explanation

Minority interest is reported on the consolidated income statement as a share of profit belonging to minority shareholders.

Alaunos Therapeutics (FRA:WEK) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alaunos Therapeutics Inc (FRA:WEK) » Definitions » Other Income (Expense)

Comparable Companies

Traded in Other Exchanges

TCRT:USA

Address

8030 El Rio Street, Houston, TX, USA, 77054

Website

https://www.alaunos.com

Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens (neoAg) arising from genomic mutations.

Alaunos Therapeutics (FRA:WEK) Headlines

No Headlines